Compare QMLS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMLS | ABOS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.4M | 197.9M |
| IPO Year | 2025 | 2021 |
| Metric | QMLS | ABOS |
|---|---|---|
| Price | $5.79 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 352.2K | 334.3K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.31 | $1.21 |
| 52 Week High | $14.82 | $3.60 |
| Indicator | QMLS | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.85 | 63.34 |
| Support Level | $5.52 | $2.13 |
| Resistance Level | $7.72 | $3.34 |
| Average True Range (ATR) | 0.71 | 0.18 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 13.91 | 61.81 |
QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.